Pay in 4 interest-free payments of $6.91 Learn more
Ships within 48 hours · Estimated delivery Sep 8 - Sep 13
Triple-Agonist Technology Retatrutide simultaneously targets: GLP-1 receptors GIP receptors Glucagon receptors This multi-pathway mechanism supports advanced metabolic research beyond single- or dual-receptor peptide models
As an investigational peptide-based injectable, retatrutide must be stored strictly in accordance with the IMP label and clinical trial protocol provided to you by the trial team
You must receive thorough, personalised instruction from your prescribing healthcare professional, GP, or a qualified nurse before attempting to inject semaglutide with a syringe yourself
How We Measure Progress Comprehensive Health Insights Gain critical insights into your overall health with advanced metrics like Visceral Fat Level and Segmental Fat Analysis
Estimated global weight loss drug sales: 2030: $93.8 billion 2029: $77.9 billion 2028: $63.7 billion 2027: $48.6 billion 2026: $35.4 billion 2025: $24.6 billion 2024: $14.8 billion 2023: $6.3 billion Source: Bloomberg Intelligence Jon Erlichman (@JonErlichman) June 22, 2024 Novo Nordisk uses semaglutide as its proprietary GLP-1 agonist in drugs that are marketed under Ozempic and Wegovy labels, with the former geared toward type-2 diabetes and the latter marketed as a treatment for obesity
US$ 22.29
US$ 25.26
US$ 25.01
US$ 22.19
US$ 29.47
US$ 25.65
